ATAINasdaq

Atai Beckley N.V.

Healthcare·Neurology·Phase 2·New York, NY, United States
NeurologyPsychiatry

Atai Beckley N.V. (ATAI): 6 pipeline candidates · ~8 mo cash runway. Updated within the last hour.

6.8/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway2.2

7.8 months

Financial Health9.2

D/E 0.50 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth9.8

6 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Atai Beckley N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$1.5B

Cash

$30.4M

Quarterly Burn

$23.3M

Runway

7.8 mo

Revenue

$749K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Feb 2027
Today~9 mo out
Catalyst within runway

Pipeline (6 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

177

Total value held

$356.4M

HolderSharesValue
vanguard capital management llc23,522,796$83.3M
deep track capital, lp12,000,000$42.5M
blackrock, inc.6,835,300$24.2M
susquehanna international group, llp6,000,126$21.2M
adage capital partners gp, l.l.c.5,642,758$20.0M
millennium management llc4,364,096$15.4M
morgan stanley3,852,772$13.6M
foresite capital management vi llc2,750,000$9.7M
geode capital management, llc2,509,974$8.9M
marshall wace, llp2,364,446$8.4M

Showing top 10 of 177 institutional holders of Atai Beckley N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·1 FDA decision·CEO: Dr. Srinivas G. Rao M.D., Ph.D.

Frequently asked questions

How many drug candidates are in Atai Beckley N.V.'s pipeline?

Atai Beckley N.V. (ATAI) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Atai Beckley N.V.'s lead drug candidate?

Atai Beckley N.V.'s most advanced tracked candidate is BPL-003 (Phase 2) for treatment-resistant depression (TRD) and alcohol use disorder (AUD).

What is Atai Beckley N.V.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Atai Beckley N.V. has approximately 7.8 months of cash runway.

What is Atai Beckley N.V.'s market capitalization?

Atai Beckley N.V.'s market capitalization is approximately $1.5B.

Who is the CEO of Atai Beckley N.V.?

Dr. Srinivas G. Rao M.D., Ph.D. is the chief executive officer of Atai Beckley N.V. (ATAI).

Get the full picture on Atai Beckley N.V.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.